Therapeutic uses of gonadotropin-releasing hormone analogs.
Since the discovery and synthesis of gonadotropin-releasing hormone (GnRH) in 1971, numerous long-acting agonistic and antagonistic analogs have been synthesized. Agonistic analogs were found to desensitize pituitary GnRH receptors with chronic use, resulting in decreased gonadotropin secretion and a hypogonadal state. These analogs are being investigated as potential contraceptives and in the treatment of several conditions in which decreased gonadal steroid production is desired. Substantial progress has been made in these areas. The purpose of this review is to provide the clinician with data regarding the potential clinical utility of this class of peptides.
D003271:Contraceptive Agents, Female; D003272:Contraceptive Agents, Male; D004715:Endometriosis / Q000188:drug therapy; D005260:Female; D006628:Hirsutism / Q000188:drug therapy; D006801:Humans; D007889:Leiomyoma / Q000188:drug therapy; D008297:Male; D010060:Ovulation / Q000187:drug effects; D010906:Pituitary Hormone-Releasing Hormones / Q000494:pharmacology / Q000627:therapeutic use*; D011293:Premenstrual Syndrome / Q000188:drug therapy; D011471:Prostatic Neoplasms / Q000188:drug therapy; D014594:Uterine Neoplasms / Q000188:drug therapy
D003271:Contraceptive Agents, Female; D003272:Contraceptive Agents, Male; D010906:Pituitary Hormone-Releasing Hormones